IGC Pharma (IGC) Research & Development (2018 - 2025)
IGC Pharma (IGC) posted quarterly Research & Development of $1.6 million for Q3 2025, up 73.17% year-over-year from $917000.0 in Q3 2024, and up 86.6% quarter-over-quarter from $851000.0 in Q2 2025.
IGC Pharma (IGC) Research & Development (2018 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Research & Development for 8 consecutive years, with $1.6 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Research & Development rose 73.17% year-over-year to $1.6 million; the TTM figure through Sep 2025 stood at $4.3 million (up 20.31% YoY), while the FY2026 annual figure was $1.3 million, down 65.2% from the prior year.
- Research & Development rose to $1.6 million in Q3 2025 per IGC's latest filing, from $851000.0 in the prior quarter.
- Across five years, Research & Development topped out at $1.6 million in Q3 2025 and bottomed at $276000.0 in Q3 2021.
- Historically, Research & Development has averaged $841684.2 across 5 years, with a median of $852000.0 in 2024.
- Annual changes were most pronounced in 2022 — Research & Development surged 269.16% — and 2023, when it tumbled 60.02%.
- IGC Pharma's Research & Development stood at $377000.0 in 2021, then surged by 113.79% to $806000.0 in 2022, then rose by 12.03% to $903000.0 in 2023, then decreased by 5.65% to $852000.0 in 2024, then jumped by 86.38% to $1.6 million in 2025.
- Business Quant data shows IGC's Research & Development at $1.6 million in Q3 2025, $851000.0 in Q2 2025, and $997000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 851,000.00 |
| Mar 31, 2025 | 997,000.00 |
| Dec 31, 2024 | 852,000.00 |
| Sep 30, 2024 | 917,000.00 |
| Jun 30, 2024 | 889,000.00 |
| Mar 31, 2024 | 855,000.00 |
| Dec 31, 2023 | 903,000.00 |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 747,000.00 |
| Mar 31, 2023 | 493,000.00 |
| Dec 31, 2022 | 806,000.00 |
| Sep 30, 2022 | 768,000.00 |
| Jun 30, 2022 | 1.39 Mn |
| Mar 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 377,000.00 |
| Sep 30, 2021 | 276,000.00 |
| Jun 30, 2021 | 444,000.00 |
| Mar 31, 2021 | 334,000.00 |
| Dec 31, 2020 | 154,000.00 |